利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.018 秒)

    HUMANIZED C5 AND C3 ANIMALS
    1.
    发明公开
    HUMANIZED C5 AND C3 ANIMALS 审中-公开

    公开(公告)号：EP4317445A2

    公开(公告)日：2024-02-07

    申请号：EP23202404.2

    申请日：2015-05-04

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： HU, Ying ,  LATUSZEK, Adrianna ,  CAO, Jingtai ,  MUJICA, Alexander ,  WIEGAND, Stanley ,  MCWHIRTER, John ,  MURPHY, Andrew ,  MACDONALD, Lynn ,  MEAGHER, Karolina

    IPC分类号： C12N15/85

    摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

    HUMANIZED C5 AND C3 ANIMALS
    5.
    发明公开
    HUMANIZED C5 AND C3 ANIMALS 审中-公开

    公开(公告)号：EP3636073A1

    公开(公告)日：2020-04-15

    申请号：EP19211905.5

    申请日：2015-05-04

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： HU, Ying ,  LATUSZEK, Adrianna ,  CAO, Jingtai ,  MUJICA, Alexander ,  WIEGAND, Stanley ,  MCWHIRTER, John ,  MURPHY, Andrew ,  MACDONALD, Lynn ,  MEAGHER, Karolina

    IPC分类号： A01K67/027 ,  A61K49/00 ,  C07K14/47 ,  C12N15/85

    摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

    HUMANIZED C5 AND C3 ANIMALS
    7.
    发明公开
    HUMANIZED C5 AND C3 ANIMALS 审中-公开
    人性化C5- UND C3-TIERE

    公开(公告)号：EP3142483A1

    公开(公告)日：2017-03-22

    申请号：EP15722639.0

    申请日：2015-05-04

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： HU, Ying ,  LATUSZEK, Adrianna ,  CAO, Jingtai ,  MUJICA, Alexander ,  WIEGAND, Stanley ,  MCWHIRTER, John ,  MURPHY, Andrew ,  MACDONALD, Lynn

    IPC分类号： A01K67/027 ,  A61K49/00 ,  C07K14/47 ,  C12N15/85

    摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

    摘要翻译： 提供了包含人或人源化C3和/或C5核酸序列的非人动物以及使用其来鉴定能够调节补体系统的化合物的方法。 描述了包含用人或人源化C5基因和/或C3基因替代内源性C5基因和/或C3基因的非人动物，以及制备和使用非人动物的方法。 还提供了包含非人C5调节元件控制下的人或人源化C5基因的非人动物，包括在人内源性C5调节元件的人C5编码序列替代非人C5编码序列的非人动物 非人C5位点。 还提供了包含非人C3调控元件控制下的人或人源化C3基因的非人动物，包括用人或人源化C3蛋白编码替代非人C3蛋白编码序列的非人动物 在内源非人C3位点的序列。 提供包含人或人源化C3和/或C5序列的非人动物，其中非人类动物是啮齿动物，例如小鼠或大鼠。

    METHODS OF USING IL-1 ANTAGONISTS TO TREAT ALZHEIMER'S DISEASE
    8.
    发明公开
    METHODS OF USING IL-1 ANTAGONISTS TO TREAT ALZHEIMER'S DISEASE 审中-公开
    使用方法IL-1拮抗剂用于治疗阿尔茨海默氏病的治疗的

    公开(公告)号：EP3003356A1

    公开(公告)日：2016-04-13

    申请号：EP14733888.3

    申请日：2014-05-30

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： CROLL, Susan, D. ,  WIEGAND, Stanley

    IPC分类号： A61K38/20 ,  A61P25/28

    CPC分类号： A61K38/1793 ,  A61K31/427 ,  A61K38/2006 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/7155 ,  C07K2319/30

    摘要： The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the disease, or condition is treated, inhibited, or ameliorated, or wherein the onset or progression of the disease, or at least one symptom of the disease, is delayed. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult suffering from Alzheimer's Disease or cerebral amyloid angiopathy.